| Literature DB >> 28758958 |
Reza Ranjbar1, Mohammad Arjomandzadegan2, Hossein Hosseiny3.
Abstract
The aim of the study was to examine antibacterial properties of microemulsion structure produced from Aloe vera var. littoralis extract as a new tool of nanoscale drug-like materials. Aloe vera var. littoralis (A. littoralis) extract was prepared by distillation method. A nonocarrier structure in the microemulsion system was prepared from the extract. Serial concentrations were prepared from 8 mg/mL extract and the nonocarrier containing 0.1 mg/mL pure extract and were evaluated by a disk diffusion method for 35 Salmonella clinical isolates. Minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) were determined by microbroth dilution assay using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) method by an enzyme-linked immunosorbent assay(ELISA) Microplate Reader apparatus. Antioxidant activity of the extract was determined by measuring the ferric reducing ability of plasma (FRAP) assay. From 35 clinical isolates of Salmonella, 17 isolates-including resistant isolates of S.E.1103 and S.E.49-had a zone of inhibition (ZI) of 7 to 32 mm in 0.007 mg/mL of the extract. S.E.76 isolate exposed to 30 µg/mL ceftazidime disk had a ZI of 12 mm but had 10 mm in 7µg/mL of A. littoralis extract. The inhibitory effect of a nanocarrier at a concentration of 25 µg/mL by 20 mm ZI was comparable by the ceftazidime (30 µg/mL) effect. MIC50 was 0.25 mg/mL and MBC50 was 0.5 mg/mL by MTT method for the extract. It was shown that A.littoralis extract had antioxidant activity of 31.67 µM/mg that could be increased based on concentration. It was concluded that the nanocarrier had a significant effect on the studied isolates in comparison with ordinary antibiotics and had potential for use as a natural antioxidant and antimicrobial material in complementary medicine.Entities:
Keywords: Aloe vera var. littoralis; Salmonella; antimicrobial properties; antioxidant activity
Year: 2017 PMID: 28758958 PMCID: PMC5620516 DOI: 10.3390/scipharm85030028
Source DB: PubMed Journal: Sci Pharm ISSN: 0036-8709
Zone of inhibition(ZI) for the clinical strains of Salmonella (in mm).
| Clinical Isolates | Concentration (mg/mL) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 8 | 4 | 2 | 1 | 0.5 | 0.25 | 0.125 | 0.062 | 0.031 | 0.015 | 0.007 | |
| 23C | 41 | 40 | 38 | 35 | 34 | 33 | 32 | 30 | 27 | 19 | 0 |
| 101D | 39 | 38 | 35 | 33 | 31 | 24 | 23 | 14 | 13 | 10 | 0 |
| S.E.49 | 42 | 40 | 37 | 37 | 35 | 34 | 28 | 22 | 20 | 15 | 10 |
| S.E.76 | 46 | 45 | 45 | 40 | 40 | 37 | 35 | 35 | 30 | 15 | 10 |
| S.F.1103 | 36 | 34 | 30 | 38 | 35 | 27 | 25 | 20 | 15 | 12 | 7 |
| S.F.ATCC | 47 | 45 | 45 | 38 | 35 | 33 | 27 | 25 | 20 | 17 | 12 |
| S.Ty.1 | 49 | 47 | 45 | 43 | 39 | 33 | 32 | 31 | 28 | 25 | 0 |
| S.Ty.151 | 44 | 43 | 39 | 37 | 35 | 33 | 30 | 29 | 27 | 26 | 0 |
| S 2 | 45 | 43 | 40 | 38 | 35 | 33 | 33 | 32 | 30 | 28 | 0 |
| S.I 1 | 43 | 41 | 37 | 33 | 29 | 28 | 23 | 20 | 17 | 13 | 0 |
| S.para1 | 37 | 36 | 32 | 32 | 32 | 32 | 31 | 31 | 28 | 25 | 0 |
| S.I.11 | 51 | 50 | 45 | 34 | 32 | 30 | 23 | 20 | 15 | 9 | 9 |
| S.I.47 | 50 | 50 | 45 | 44 | 41 | 39 | 36 | 34 | 33 | 27 | 25 |
| S.E.101 | 40 | 39 | 34 | 34 | 30 | 27 | 24 | 19 | 10 | 10 | 9 |
| S.E.24 | 50 | 50 | 45 | 37 | 34 | 34 | 26 | 21 | 16 | 13 | 7 |
| S.Ty.21 | 39 | 37 | 34 | 36 | 33 | 31 | 26 | 24 | 19 | 15 | 10 |
| S 87D | 42 | 40 | 32 | 30 | 30 | 28 | 25 | 20 | 15 | 10 | 0 |
| S 65 D | 41 | 39 | 37 | 36 | 32 | 26 | 22 | 18 | 12 | 12 | 0 |
| 159 | 33 | 30 | 27 | 25 | 24 | 20 | 17 | 14 | 11 | 0 | 0 |
| 46 | 37 | 36 | 28 | 27 | 24 | 23 | 23 | 21 | 21 | 14 | 0 |
| 93 | 45 | 44 | 40 | 34 | 30 | 30 | 30 | 25 | 19 | 14 | 10 |
| 75 | 47 | 46 | 38 | 37 | 36 | 30 | 28 | 27 | 19 | 17 | 0 |
| 95 | 43 | 41 | 38 | 35 | 31 | 30 | 29 | 24 | 19 | 15 | 0 |
| 69 | 39 | 38 | 32 | 30 | 38 | 26 | 23 | 18 | 15 | 11 | 0 |
| 62 | 42 | 40 | 36 | 33 | 30 | 28 | 17 | 21 | 17 | 17 | 12 |
| 123 | 38 | 36 | 34 | 30 | 28 | 24 | 22 | 19 | 17 | 11 | 0 |
| 94 | 39 | 37 | 32 | 30 | 28 | 26 | 26 | 22 | 17 | 14 | 0 |
| 128 | 42 | 40 | 36 | 30 | 28 | 25 | 22 | 19 | 15 | 0 | 0 |
| 150 | 47 | 46 | 38 | 32 | 30 | 29 | 27 | 29 | 23 | 18 | 0 |
| 122 | 45 | 43 | 34 | 30 | 27 | 26 | 25 | 21 | 18 | 16 | 14 |
| 87 | 58 | 57 | 53 | 48 | 44 | 41 | 38 | 35 | 32 | 24 | 20 |
| 55 | 43 | 41 | 40 | 37 | 32 | 25 | 22 | 16 | 15 | 12 | 10 |
| 152 | 56 | 55 | 52 | 50 | 47 | 44 | 41 | 39 | 37 | 33 | 28 |
| 156 | 58 | 57 | 54 | 50 | 47 | 44 | 42 | 39 | 34 | 33 | 32 |
| 76 | 52 | 51 | 49 | 48 | 44 | 44 | 38 | 35 | 32 | 30 | 27 |
Figure 1The susceptibility results of Salmonella isolates to the serial (maximum) concentrations of Aloe vera var. littoralis extract .
Figure 2Disk diffusion results for various concentrations of the nanoform of Aloe vera extract on Salmonella 123. A: 0.125 mg/mL; B: 0.062 mg/mL; C: 0.031 mg/mL.
The inhibitory growth zones by the studied isolates exposed to antibiogram discs.
| Isolates | Antibiotic (mm) | |||
|---|---|---|---|---|
| CAZ | CIP | AM | GM | |
| 152 | 18 | 36 | 25 | 27 |
| 150 | R | 40 | 20 | 33 |
| 221 | R | 40 | 20 | 33 |
| 94 | R | 35 | 19 | 32 |
| 62 | 22 | 38 | 20 | 30 |
| 156 | 16 | 40 | 23 | 33 |
| 87 | R | 45 | 12 | 34 |
| 95 | R | 35 | 19 | 34 |
| 75 | R | 35 | 20 | 30 |
| 46 | R | 40 | 14 | 28 |
| 93 | R | 35 | 19 | 29 |
| 123 | R | 32 | 20 | 28 |
| 128 | R | 32 | 19 | 30 |
| 76 | 16 | 31 | 24 | 31 |
| S.E.49 | R | 38 | R | 18 |
| S.E.76 | 12 | 44 | 10 | 22 |
| S.E.1103 | 18 | 40 | R | R |
| S.E.ATCC | 10 | R | R | R |
CAZ: Ceftazidime (30 µg); CIP: Ciprofloxacin (5 µg); AM: Ampicillin (10 µg); GM: Gentamicin (10 µg); R: Resistant.
Figure 3The results of minimum inhibitory concentration(MIC) determined by microdilution method (OD versus concentrations) for two salmonella strains. Concentrations of A. littoralis extract in wells 1–12were 4, 2, 1, 0.5, 0.25, 0.125, 0.062, 0.031, 0.015, and 0.007 mg/mL, respectively ( wells 11 and 12 were controls).
Figure 4Standard curve for ferric reducing ability of plasma (FRAP) assay.